Toni K. Choueiri: LITESPARK-005 is out
Toni K. Choueiri shared on LinkedIn:
“LITESPARK-005 is out in NEJM Group —First in class HIF2 inhibitor Belzutifan is superior to Everolimus in advanced refractory Renal Cancer —Thank you to all study participants and the investigators!”
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Authors: Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suarez, Pooja Ghatalia, Roberto Iacovelli, Elaine T.Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross-Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry A. Nosov, Camillo Porta, Jae Lyun Lee, Xavier Garcia-del-Muro, Elisa Biscaldi, Ray Manneh Kopp, Mototsugu Oya, Li He, Aobo Wang, Rodolfo F.Perini, Donna Vickery, Laurence Albiges, Brian Rini,
Source: Toni K. Choueiri/LinkedIn
For more posts by Toni K. Choueiri, visit oncodaily.com
Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
